Kadmon Announces Oral Presentation on KD025 in cGVHD at EHA Congress
May 17 2018 - 9:02AM
Business Wire
Kadmon Holdings, Inc. (NYSE:KDMN) today announced that
additional data from its ongoing Phase 2 clinical trial of KD025 in
chronic graft-versus-host disease (cGVHD) will be highlighted in an
oral presentation at the 23rd Congress of the European Hematology
Association (EHA), to be held June 14-17, 2018 in Stockholm,
Sweden.
Details for the presentation are as follows:
EHA Presentation
DetailsDate & Time: Saturday, June 16, 4:30 –
4:45 p.m. CESTTitle: KD025-208: A Phase 2 Open-Label Trial
of KD025 for Steroid-Dependent Chronic Graft-Versus-Host Disease
(cGVHD)
About KD025KD025 is a selective oral inhibitor of
Rho-associated coiled-coil kinase 2 (ROCK2), a signaling pathway
that mediates cell movement, shape, differentiation and function
and is dysregulated in many chronic diseases, including cGVHD. In
October 2017, KD025 received orphan drug designation from the U.S.
Food and Drug Administration (FDA) for cGVHD. In April 2018, based
on FDA guidance, Kadmon announced a planned open-label, pivotal
study of KD025 in cGVHD.
About cGVHDcGVHD is a common and often fatal complication
following hematopoietic stem cell transplantation, a procedure that
is often used to treat patients with cancers such as myeloma or
leukemia. With cGVHD, transplanted immune cells (graft) attack the
patient’s cells (host), leading to inflammation and fibrosis in
multiple tissues, including skin, mouth, eye, joints, liver, lung,
esophagus and GI tract.
About Kadmon Holdings, Inc.Kadmon Holdings, Inc. is a
fully integrated biopharmaceutical company developing innovative
products for significant unmet medical needs. Our product pipeline
is focused on inflammatory and fibrotic diseases.
Forward Looking StatementsThis press release contains
forward-looking statements. Such statements may be preceded by the
words “may,” “will,” “should,” “expects,” “plans,” “anticipates,”
“could,” “intends,” “targets,” “projects,” “contemplates,”
“believes,” “estimates,” “predicts,” “potential” or “continue” or
the negative of these terms or other similar expressions.
Forward-looking statements involve known and unknown risks,
uncertainties and other important factors that may cause our actual
results, performance or achievements to be materially different
from any future results, performance or achievements expressed or
implied by the forward-looking statements. We believe that these
factors include, but are not limited to, (i) the initiation,
timing, progress and results of our preclinical studies and
clinical trials, and our research and development programs; (ii)
our ability to advance product candidates into, and successfully
complete, clinical trials; (iii) our reliance on the success of our
product candidates; (iv) the timing or likelihood of regulatory
filings and approvals; (v) our ability to expand our sales and
marketing capabilities; (vi) the commercialization of our product
candidates, if approved; (vii) the pricing and reimbursement of our
product candidates, if approved; (viii) the implementation of our
business model, strategic plans for our business, product
candidates and technology; (ix) the scope of protection we are able
to establish and maintain for intellectual property rights covering
our product candidates and technology; (x) our ability to operate
our business without infringing the intellectual property rights
and proprietary technology of third parties; (xi) costs associated
with defending intellectual property infringement, product
liability and other claims; (xii) regulatory developments in the
United States, Europe and other jurisdictions; (xiii) estimates of
our expenses, future revenues, capital requirements and our needs
for additional financing; (xiv) the potential benefits of strategic
collaboration agreements and our ability to enter into strategic
arrangements; (xv) our ability to maintain and establish
collaborations or obtain additional grant funding; (xvi) the rate
and degree of market acceptance of our product candidates; (xvii)
developments relating to our competitors and our industry,
including competing therapies; (xviii) our ability to effectively
manage our anticipated growth; (xix) our ability to attract and
retain qualified employees and key personnel; (xx) our ability to
achieve cost savings and other benefits from our efforts to
streamline our operations and to not harm our business with such
efforts; (xxi) the use of proceeds from our recent public
offerings; (xxii) the potential benefits of any of our product
candidates being granted orphan drug designation; (xxiii) the
future trading price of the shares of our common stock and impact
of securities analysts’ reports on these prices; and/or (xxiv)
other risks and uncertainties. More detailed information about
Kadmon and the risk factors that may affect the realization of
forward-looking statements is set forth in the Company’s filings
with the U.S. Securities and Exchange Commission (the “SEC”),
including the Company’s Quarterly Report on Form 10-Q filed
pursuant to Section 13 of the Securities Exchange Act of 1934, as
amended, with the SEC on May 8, 2018. Investors and security
holders are urged to read these documents free of charge on the
SEC’s website at www.sec.gov. The Company assumes no obligation to
publicly update or revise its forward-looking statements as a
result of new information, future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180517005411/en/
Investor RelationsKadmon Holdings, Inc.Ellen Tremaine,
646-490-2989ellen.tremaine@kadmon.com
Kadmon (NYSE:KDMN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Kadmon (NYSE:KDMN)
Historical Stock Chart
From Sep 2023 to Sep 2024